PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS
申请人:GRI Bio, Inc.
公开号:EP3229811B1
公开(公告)日:2021-02-24
[EN] PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS<br/>[FR] PRÉVENTION ET TRAITEMENT DE PATHOLOGIES INFLAMMATOIRES
申请人:GLYCOREGIMMUNE INC
公开号:WO2016094226A1
公开(公告)日:2016-06-16
In accordance with some embodiments herein, methods and compositions for prevention and treatment of inflammatory conditions are provided. In some embodiments, compositions comprising NKT-2 activators, for example miltefosine are provided. In some embodiments, the compositions further comprise sulfatide and/or a RAR agonist. In some embodiments, the compositions comprise activators of Type II NKT cells, and/or inhibitors of Type I NKT cells.
Lipid-like sulfoxides and amine oxides as inhibitors of mast cell activation
immunoglobulin E receptor-dependent mastcellactivation. Miltefosine and other alkylphospholipids that are active in mastcelldegranulation assays contain a positively charged nitrogen and a phosphate group that are important for activity. In addition to alkylphospholipids, ceramides are also known to act on membrane environments and inhibitmastcellactivation. We have systematically searched a